The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sulfonylureas are an effective and inexpensive treatment for type 2 diabetes. There is conflicting data about the safety of these drugs regarding mortality and cardiovascular outcomes. The objective of the present study was to evaluate the safety of the sulfonylureas most frequently used and to use trial sequential analysis (TSA) to analyze whether the available sample was powered enough to support the results. METHODS AND FINDINGS: Electronic databases were reviewed from 1946 (Embase) or 1966 (MEDLINE) up to 31 December 2014. Randomized clinical trials (RCTs) of at least 52 wk in duration evaluating second- or third-generation sulfonylureas in the treatment of adults with type 2 diabetes and reporting outcomes of interest were included. Primary outcomes were all-cause and cardiovascular mortality. Additionally, myocardial infarction and stroke events were evaluated. Data were summarized with Peto odds ratios (ORs), and the reliability of the results was evaluated with TSA. Forty-seven RCTs with 37,650 patients and 890 deaths in total were included. Sulfonylureas were not associated with all-cause (OR 1.12 [95% CI 0.96 to 1.30]) or cardiovascular mortality (OR 1.12 [95% CI 0.87 to 1.42]). Sulfonylureas were also not associated with increased risk of myocardial infarction (OR 0.92 [95% CI 0.76 to 1.12]) or stroke (OR 1.16 [95% CI 0.81 to 1.66]). TSA could discard an absolute difference of 0.5% between the treatments, which was considered the minimal clinically significant difference. The major limitation of this review was the inclusion of studies not designed to evaluate safety outcomes. CONCLUSIONS: Sulfonylureas are not associated with increased risk for all-cause mortality, cardiovascular mortality, myocardial infarction, or stroke. Current evidence supports the safety of sulfonylureas; an absolute risk of 0.5% could be firmly discarded. REVIEW REGISTRATION: PROSPERO CRD42014004330.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The following drug classes were excluded due to lack of current evidence of efficacy in cardiovascular outcome trials: dipeptidyl peptidase-4 inhibitors,19 sulfonylureas,20 and insulin.21,22”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sulphonylurea monotherapy for patients with type 2 diabetes mellitus
Hemmingsen, B., Schroll, J. B., Lund, S. S., Wetterslev, J., Gluud, C., Vaag, A., Sonne, D. P., Lundstrøm, L. H., & Almdal, T. P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009008.pub2 · Cited by 88 · cited 3×
“These contradictory results may be explained by the inclusion, or not, of first-generation sulfonylureas [19,20], observational studies [21,22], and short-term studies [18–21].”
BackgroundResultRetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 6×
“Therefore, the search strategy included the terms “type 2 diabetes” and “sulfonylureas” and used the recommended, highly sensitive Cochrane Collaboration strategy for RCT systematic reviews [26].”
BackgroundMethodInfluentialDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Research works printed but not linked: 1
- Li MK, Liu Q, Yu ZZ, Cui SM, Shi P, et al (1999) [ Observation of the effect of combination of glipizide and insulin for type2 diabetic patients with secondary failure to oral sulfonylureas]. J Clin Int Med 15: 38.
Cited by
Items 101–143 of 143
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
Natural Diabetes Treatment with Litchi Seeds Extract In Vivo
Shohel, M. A., Tang, A. K., Sailaja, I., Islam, T. M. T., Kabir, M. H., Mahat, N. C., & Shaker, I. A. (2024) · Journal of Angiotherapy · doi:10.25163/angiotherapy.879738 · Cited by 5
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 8
Arnold, S. V., McGuire, D. K., Inzucchi, S. E., Tang, F., Mehta, S. N., Lam, C. S. P., Goyal, A., Sperling, L. S., Wong, N. D., Hammar, N., et al. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.02.009 · Cited by 4
Nasrallah, M., Khalil, C. A., & Refaat, M. M. (2017) · BioMed Research International · doi:10.1155/2017/9257930 · Cited by 5
“Most recently, a meta-analysis which included 47 randomized trials using second- or third-generation SUs against placebo or as add-on to metformin revealed no increase in CV risk [23].”
BackgroundAntihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence
Gale, S. E., Poon, J. L., & Watson, K. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2128 · Cited by 3
“12).(30) The effects of sulfonylureas with respect to CV risk have been described previously.”
BackgroundVércukorcsökkentő gyógyszerek biztonságossága szívelégtelenségben
Frigy, A., Germán-Salló, M., Máthé, L., & Szabó, M. (2017) · Orvosi Hetilap · doi:10.1556/650.2017.30652 · Cited by 3
The impact of glucose-lowering medications on cardiovascular disease
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2017) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000139 · Cited by 5
López, A. A. P., Chávez-Negrete, A., Rodríguez-Lozano, A. L., Gómez-Alarcón, Á. J., Montaño-Velázquez, B. B., Hinojosa, C. A., Sánchez-Hernández, C., Pimentel-Hernández, C., Dehesa-López, E., Romero-Moreno, F., et al. (2026) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m23000030 · Cited by 9
Cardiovascular outcome trials in type 2 diabetes: A critical analysis
Ashraf, H., & Ahmad, J. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.09.001 · Cited by 3
Maximizing treatment benefits in type 2 diabetes by affordable oral anti diabetes agents in India
Das, A. K., Krishnakumar, B., Ajish, T., Sheohare, R., & Chittawar, S. (2021) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20213722 · Cited by 2
“The analysis revealed that Modern SUs are not associated with an increased risk of myocardial infarction, all-cause and cardiovascular mortality.(28) Figure 2 explains the various pleiotropic benefits of modern SUs.”
BackgroundGliclazide MV: Proven Efficacy and Safety
Ivannikova, E. V., & Dudinskaya, Е. N. (2023) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2023-19-1-32-38 · Cited by 2
Utility and benefits of sulfonylureas beyond glycemic control
Jayakrishnan, B. (2022) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20220442 · Cited by 2
Голубев, С. А. (2024) · Рецепт · doi:10.34883/pi.2024.27.1.002 · Cited by 2
Writers, A. M. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00619-7 · Cited by 1
“MOA ↑ Insulin section through pancreatic beta cells Place in therapy Dual or triple therapy ± metformin; limited use in elderly because of ↑ risk of hypoglycaemia Effectiveness Generally acceptable for pts without CVD, with predictable efficacy Safety profile ↑ Risk of hypoglycaemia (especially with long-acting glybur…”
BackgroundLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
Delbaere, J., Deboever, E., Vaes, B., Nobels, F. R. E., Mamouris, P., & Goderis, G. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.003 · Cited by 1
Scherbaum, W. A., & Hamann, A. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0356-5 · Cited by 1
Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure
Talha, K. M., Fonarow, G. C., Virani, S. S., & Butler, J. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1155 · Cited by 1
Rhee, S. Y. (2018) · Journal of Korean Diabetes · doi:10.4093/jkd.2018.19.1.15 · Cited by 1
Nonglycemic Outcomes of Antidiabetic Medications
Morse, C., Sze, D., Patel, D. K., & Goldman, J. D. (2018) · Clinical Diabetes · doi:10.2337/cd18-0015 · Cited by 1
“Researchers in this analysis found no significant increase in risk of all-cause CV mortality, MI, or stroke (5).”
BackgroundBurton, J. K., Quinn, T. J., & Fisher, M. (2019) · Practical Diabetes · doi:10.1002/pdi.2230 · Cited by 2
Noninsulin Therapy for Diabetes
Maxson, R., & McCoy, E. K. (2020) · Physician Assistant Clinics · doi:10.1016/j.cpha.2019.11.005 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
“[47] Rados DV, Pinto LC, Remonti LR et al.”
Greener, M. (2016) · Nurse Prescribing · doi:10.12968/npre.2016.14.6.272
Lessons from Recent Cardiovascular Outcome Trials of Type 2 Diabetes
Kim, N. H., & Kim, S. G. (2017) · Journal of Korean Diabetes · doi:10.4093/jkd.2017.18.1.7
Llover, M. N., & Jiménez, M. C. (2017) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2017.01.007
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_19-1
Zhuravlyova, L., & Filonenko, M. (2019) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.2.2019.166106
Deed, G., Atherton, J. J., dʼEmden, M. C., Rasalam, R. R., Sharma, A. K., & Sindone, A. P. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0663-x · Cited by 1
Ruquiyyah, K., & Hoda, Q. (2020) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2020.7.1.0242
“Most recently, a meta-analysis that included 47 randomized trials using second- or third-generation SUs against placebo or as an add-on to metformin revealed no increase in CV risk [21].”
BackgroundMesa 3: Efectos cardiovasculares de fármacos antidiabéticos
Ávila, P. J., Milrad, S. A., Forlino, M., Fábregues, S., Vázquez, F., Grosso, C., Schindler, A., Zambon, F., Rodríguez, M. V., Santos, N. C. G., et al. (2020) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v54i2sup.253
MARKET OF ORAL ANTIDIABETIC DRUGS IN THE REPUBLIC OF CRIMEA
SHEIKHMAMBETOVA, L. N., Егорова, С. Н., EGOROVA, E. A., & Bekirova, E. Y. (2021) · The Bulletin of Contemporary Clinical Medicine · doi:10.20969/vskm.2021.14(4).35-41 · Cited by 1
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_19
Bertoluci, M. C., Júnior, W. S. D. S., Valente, F., Araujo, L. R., Lyra, R., de Castro, J. J., Raposo, J. F., Miranda, P. A. C., Boguszewski, C. L., Hohl, A., et al. (2023) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/na230038 · Cited by 1
Self-citationKroon, L. A., & Zhou, C. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch08
Volke, V., Katus, U., Johannson, A., Toompere, K., Heinla, K., Rünkorg, K., & Uusküla, A. (2022) · Figshare · doi:10.6084/m9.figshare.21366056
Volke, V., Katus, U., Johannson, A., Toompere, K., Heinla, K., Rünkorg, K., & Uusküla, A. (2022) · Figshare · doi:10.6084/m9.figshare.21366059
Volke, V., Katus, U., Johannson, A., Toompere, K., Heinla, K., Rünkorg, K., & Uusküla, A. (2022) · Figshare · doi:10.6084/m9.figshare.21366062
Gliklazid – a szulfonilurea csoport preferálandó származéka
Winkler, G., Kempler, P., & Lengyel, C. (2025) · Diabetologia Hungarica · doi:10.24121/dh.2025.34
Yang, Z., Jiao, Y., Sun, Y., Wu, Y., Xu, L., Zhang, J., Yu, L., Shen, P., Lin, H., Shui, L., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70564
“31 More recent real-world studies have consistently demonstrated a relative disadvantage of sul-fonylurea compared with metformin.”
Jiang, X., Hirschmüller, N., Taylor, H. J., Dalakoti, M., Needham, E. J., Kelemen, M., Jiang, T., Ritchie, S. C., Vidal‐Puig, A., Butterworth, A. S., et al. (2026) · medRxiv · doi:10.64898/2026.08.24.26361276
Metadata
- Authors
- Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L.
- Affiliations
- Universidade Federal do Rio Grande do Sul (BR)
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-04-12
- Volume
- 13
- Issue
- 4
- Pages
- e1001992
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC4829174
- OpenAlex
- W2341376576
- Cited by
- 143
- References
- 102
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 8 · 2023: 11 · 2022: 18 · 2021: 11 · 2020: 20 · 2019: 17 · 2018: 23 · 2017: 24 · 2016: 4
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-06-24)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- sulfonylureas, type 2 diabetes, drug safety, all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, trial sequential analysis, sample size adequacy
- MeSH terms
- Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Risk Factors, Sulfonylurea Compounds, Time Factors, Chi-Square Distribution, Odds Ratio, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.